CRISPR Therapeutics AG Cash Flow Statement (2015-2026) | CRSP

Cash Flow Statement Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
759.23M-127.15M-141.25M-179.22M-185.82M-174.55M-110.58M-53.06M-77.74M-112.14M89.39M-116.59M-126.42M-85.94M366.59M-135.99M-208.55M-106.44M-162.25M-122.93M
Depreciation and Depletion (Quarter)
3.60M5.30M6.20M6.00M7.30M5.00M5.80M5.00M5.00M4.90M4.90M4.80M4.80M4.80M4.80M4.70M4.60M4.40M5.60M4.30M
Share-based Compensation (Quarter)
28.33M26.20M25.77M25.75M24.85M24.54M22.80M20.88M21.77M19.97M18.39M19.41M23.67M21.54M21.95M20.21M17.61M60.10M18.08M72.30M
Asset Writedowns and Impairment (Quarter)
Cash from Operations (Quarter)
807.00M-81.33M-86.04M-135.24M-141.96M-105.22M-113.33M8.80M-133.25M-39.86M-96.07M109.75M-95.58M-106.91M-50.03M-53.95M-113.88M-84.63M-92.55M-108.90M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) (Quarter)
3.65M5.32M6.26M6.04M7.27M5.02M5.85M5.05M4.96M4.92M4.90M4.83M4.84M4.74M4.84M4.74M4.65M4.43M5.66M4.32M
Change in Working Capital
Change in Receivables (Quarter)
0.00M0.15M-0.16M-0.08M-0.02M-0.05M70.00M-70.00M200.00M-200.00M25.00M-25.00M
Change in Accured Expenses (Quarter)
-2.10M20.60M22.78M-0.15M-0.99M-1.03M0.65M25.21M-11.58M-24.69M-9.19M-0.43M19.16M-19.09M-26.92M43.00M-14.70M12.18M4.42M-0.20M
Other Working Capital Changes (Quarter)
4.40M9.30M-4.86M-4.61M2.58M-5.03M5.46M-12.04M-3.91M-0.82M-6.45M-2.95M-2.35M0.19M-0.18M0.63M0.09M-0.21M-3.85M0.25M
Investing Activities
Capital Expenditures (Quarter)
26.63M37.05M9.18M5.89M19.09M-20.06M-2.80M3.06M-2.03M-0.28M-0.03M0.72M0.71M0.22M-1.49M0.21M0.12M0.07M0.52M0.50M
Change in Acquisitions & Divestments (Quarter)
126.82M142.67M123.01M223.97M227.55M419.75M325.06M386.51M408.71M369.87M287.43M237.34M349.78M247.68M373.00M186.18M310.18M214.93M-710.59M192.76M
Cash from Investing Activities (Quarter)
-293.64M-565.18M-8.72M-114.52M-56.07M87.46M-175.53M117.83M216.92M121.35M-81.45M-97.80M-126.91M-161.60M105.83M-19.75M69.98M-119.23M37.20M-410.74M
Financing Activities
Other financing activities (Quarter)
9.77M10.21M6.30M10.65M10.35M14.14M2.48M5.40M16.77M1.56M6.22M25.19M0.55M3.64M1.92M2.07M2.28M18.66M4.92M6.16M
Cash from Financing Activities (Quarter)
8.44M10.21M6.30M10.65M10.35M15.11M2.48M5.40M16.77M1.56M38.94M305.93M-0.47M9.64M16.88M10.59M2.26M296.77M116.41M591.91M
Change in Capital Stock
Net Equity Issued and Repurchased (Quarter)
-1.32M0.97M32.72M280.75M-1.01M6.00M14.96M8.52M71.30M71.30M305.60M-0.72M
Additional items
Exchange Rate Effect (Quarter)
0.01M-0.02M0.00M-0.03M-0.07M-0.10M0.12M0.03M0.03M-0.05M0.06M-0.01M0.00M0.07M-0.09M0.04M0.08M-0.03M0.00M-0.03M
Change in Cash (Quarter)
521.81M-636.32M-88.45M-239.13M-187.74M-2.74M-286.27M132.06M100.47M83.00M-138.53M317.88M-222.95M-258.80M72.59M-63.07M-41.56M92.88M61.06M72.24M
Free Cash Flow (Quarter)
780.38M-118.38M-95.22M-141.13M-161.05M-85.16M-110.53M5.74M-131.22M-39.58M-96.05M109.03M-96.29M-107.13M-48.54M-54.15M-114.00M-84.71M-93.07M-109.40M
Net Cash Flow (Quarter)
521.81M-636.30M-88.45M-239.10M-187.68M-2.64M-286.38M132.03M100.44M83.05M-138.59M317.89M-222.95M-258.88M72.67M-63.11M-41.65M92.91M61.06M72.27M